FINAL RESULTS AND PHARMACOECONOMIC ANALYSIS OF A TRIAL COMPARING TWO NEOADJUVANT CHEMOTHERAPY (CT) REGIMENS FOLLOWED BY SURGERY IN PATIENTS WITH RESECTABLE NON-SMALL CELL LUNG CANCER (NSCLC): A PHASE II RANDOMISED STUDY BY THE EUROPEAN LUNG CANCER WORKING PARTY

被引：0
|
作者：
Berghmans, Thierry
Lafitte, Jean-Jacques [1 ]
Giner, Vicente
Berchier, Marie-Claude
Scherpereel, Arnaud [1 ]
Lewin, Daniel
Paesmans, Marianne
Meert, Anne-Pascale
Bosschaerts, Thierry [2 ]
Leclercq, Nathalie
Sculier, Jean-Paul
机构：
[1] CHRU Lille, Lille, France
[2] Hop St Pierre, St Pierre, Belgium
来源：
JOURNAL OF THORACIC ONCOLOGY | 2011年 / 6卷 / 06期
关键词：
Non small cell lung carcinoma; Surgery; neoadjuvant chemotherapy; Cost-effectiveness;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S465 / S466
页数：2
相关论文
共 50 条
  • [31] Phase II study of docetaxel plus gemcitabine in patients with non-small cell lung cancer (NSCLC) that failed previous chemotherapy (CT).
    Chen, YM
    Perng, RP
    Whang-Peng, J
    Lin, WC
    Wu, HW
    Tsai, CM
    ANNALS OF ONCOLOGY, 2000, 11 : 115 - 115
  • [32] A Phase I/II Study of Neoadjuvant Cisplatin, Docetaxel, and Nintedanib for Resectable Non-Small Cell Lung Cancer
    Cascone, Tina
    Sepesi, Boris
    Lin, Heather Y.
    Kalhor, Neda
    Parra, Edwin R.
    Jiang, Mei
    Godoy, Myrna C. B.
    Zhang, Jianjun
    Fossella, Frank, V
    Tsao, Anne S.
    Lam, Vincent K.
    Lu, Charles
    Mott, Frank E.
    Simon, George R.
    Antonoff, Mara B.
    Mehran, Reza J.
    Rice, David C.
    Behrens, Carmen
    Weissferdt, Annikka
    Moran, Cesar
    Vaporciyan, Ara A.
    Lee, J. Jack
    Swisher, Stephen G.
    Gibbons, Don L.
    Wistuba, Ignacio I.
    William, William N., Jr.
    Heymach, John, V
    CLINICAL CANCER RESEARCH, 2020, 26 (14) : 3525 - 3536
  • [33] A phase II study of erlotinib followed by chemotherapy on progression in an unselected population of advanced non-small cell lung cancer (NSCLC) patients.
    Horn, Leora
    Li, Chung-I
    Pao, William
    Keedy, Vicki Leigh
    Johnson, David H.
    Carbone, David P.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [34] Neoadjuvant tislelizumab or placebo plus platinum-based chemotherapy followed by adjuvant tislelizumab or placebo in patients with resectable non-small cell lung cancer (NSCLC): A phase III trial in progress
    Wang, C.
    Wang, R.
    Ma, Y.
    Liang, X.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S746 - S746
  • [35] Neoadjuvant chemotherapy and radiotherapy followed by surgery in selected patients with stage IIIB non-small-cell lung cancer: a multicentre phase II trial
    Stupp, Roger
    Mayer, Michael
    Kann, Roger
    Weder, Walter
    Zouhair, Abderahim
    Betticher, Daniel C.
    Roth, Arnaud D.
    Stahel, Rolf A.
    Majno, Sabine Balmer
    Peters, Solange
    Jost, Lorenz
    Furrer, Markus
    Thierstein, Sandra
    Schmid, Ralph A.
    Hsu-Schmitz, Shu-Fong
    Mirimanoff, Rene-Olivier
    Ris, Hans-Beat
    Pless, Miklos
    LANCET ONCOLOGY, 2009, 10 (08): : 785 - 793
  • [36] Phase II trial of neoadjuvant osimertinib for surgically resectable EGFR-mutated non-small cell lung cancer
    Aredo, Jacqueline V.
    Urisman, Anatoly
    Gubens, Matthew A.
    Mulvey, Claire
    Allen, Greg M.
    Rotow, Julia K.
    Kerr, Daniel Lucas
    Chakrabarti, Turja
    Bacaltos, Bianca
    Gee, Megan
    Jones, Kirk
    Aisner, Dara L.
    Patil, Tejas
    Schenk, Erin Lynn
    Bivona, Trever G.
    Riess, Jonathan W.
    Coleman, Melissa
    Kratz, Johannes Ruediger
    Jablons, David
    Blakely, Collin M.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [37] Open non-randomised phase II pilot study of neoadjuvant cetuximab in combination with cisplatin and gemcitabine in patients with resectable non-small cell lung cancer
    Coate, Linda E.
    Cuffe, Sinead
    McDowell, Dermot
    Gately, Kathy
    Barr, Martin
    Meaney, James
    O'Connell, Finbarr
    Nicholson, Siobhan
    Young, Vincent
    O'Byrne, Kenneth
    JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) : S412 - S412
  • [38] Neoadjuvant toripalimab plus chemotherapy in patients with potentially resectable non-small cell lung cancer: A prospective, single-arm, phase II trial (Renaissance Study)
    Yan, S.
    Chen, J.
    Wang, J.
    Lv, C.
    Bi, J.
    Yang, X.
    Li, S.
    Wang, Y.
    Li, X.
    Yang, Y.
    Wu, N.
    ANNALS OF ONCOLOGY, 2021, 32 : S1400 - S1400
  • [39] Single agent weekly paclitaxel chemotherapy in elderly or frail non-small cell lung cancer (NSCLC) patients:: Final results of a phase II trial Spanish Lung Cancer Group (GECP 00/02)
    Massuti, B
    Camps, C
    Garrido, P
    Viñolas, N
    Barcelo, J
    Barneto, I
    Guillot, M
    Jiménez, M
    Bover, I
    Sanchez-Paya, J
    LUNG CANCER, 2005, 49 : S258 - S258
  • [40] Combination therapy of envafolimab and suvemcitug with chemotherapy in patients with non-small cell lung cancer (NSCLC): Results from a phase II clinical trial
    Wu, C.
    Wu, L.
    Meng, X.
    Wang, Y.
    Fan, Q.
    Wang, X.
    Gu, K.
    Ma, R.
    Hu, C.
    Lu, L.
    Su, F.
    Yang, C.
    Liu, Z.
    Tian, J.
    Sun, X.
    Sun, S.
    Cheng, Y.
    ANNALS OF ONCOLOGY, 2023, 34
12345